Cynthia Behling

机构：University of California System, University of California San Diego, Pacific Rim Engineering (United States), Pacific Clinical Research, Pacific Medical (China) · ORCID：0000-0001-7016-2636

发表论文 164 篇 · 总被引 23349 次 · h-index 48

代表论文

• Efruxifermin in Compensated Liver Cirrhosis Caused by MASH (2025 · New England Journal of Medicine · 被引 111)
• Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial (2025 · The Lancet · 被引 57)
• MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH (2024 · Gut · 被引 37)
• Liver stiffness progression in biopsy-proven metabolic dysfunction–associated steatotic disease among people with diabetes versus people without diabetes: A prospective multicenter study (2024 · Hepatology · 被引 31)
• MASLD: What We Have Learned and Where We Need to Go—A Call to Action (2024 · Radiographics · 被引 27)
• Aramchol improves hepatic fibrosis in metabolic dysfunction–associated steatohepatitis: Results of multimodality assessment using both conventional and digital pathology (2024 · Hepatology · 被引 27)